Pasithea Therapeutics Company Insiders
| KTTAW Stock | USD 0.02 0 8.97% |
Pasithea Therapeutics employs about 8 people. The company is managed by 8 executives with a total tenure of roughly 19 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Recap of Pasithea Therapeutics' management performance can provide insight into the venture performance.
Pasithea |
Pasithea Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.379) % which means that it has lost $0.379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.6325) %, meaning that it generated substantial loss on money invested by shareholders. Pasithea Therapeutics' management efficiency ratios could be used to measure how well Pasithea Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to climb to -0.9 in 2024. Return On Capital Employed is likely to drop to -0.71 in 2024. At this time, Pasithea Therapeutics' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to climb to about 464.2 K in 2024, despite the fact that Non Currrent Assets Other are likely to grow to (8.7 B).Common Stock Shares Outstanding is likely to drop to about 1.2 M in 2024
Pasithea Therapeutics Workforce Comparison
Pasithea Therapeutics Corp is rated fifth overall in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 248. Pasithea Therapeutics holds roughly 8.0 in number of employees claiming about 3% of equities under Health Care industry.
Pasithea Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Pasithea Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Pasithea Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Pasithea Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Dumesnil Simon 3 days ago Acquisition by Dumesnil Simon of 10000 shares of Pasithea Therapeutics at 1.07 subject to Rule 16b-3 | ||
Pd Joint Holdings, Llc Series 2016-a over three months ago Disposition of tradable shares by Pd Joint Holdings, Llc Series 2016-a of Pasithea Therapeutics subject to Rule 16b-3 | ||
Abramowitz Israel Maxx over six months ago Discretionary transaction by Abramowitz Israel Maxx of tradable shares of Pasithea Therapeutics subject to Rule 16b-3 | ||
Tiago Marques over six months ago Disposition of tradable shares by Tiago Marques of Pasithea Therapeutics subject to Rule 16b-3 |
Pasithea Therapeutics Notable Stakeholders
A Pasithea Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Pasithea Therapeutics often face trade-offs trying to please all of them. Pasithea Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Pasithea Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| BA MD | Executive CoFounder | Profile | |
| Tiago MD | CEO Director | Profile | |
| Yassine Bendiabdallah | COO Clinics | Profile | |
| Stanley Gloss | Chief Officer | Profile | |
| MD BA | Ex CoFounder | Profile | |
| Tiago Marques | CEO Director | Profile | |
| Daniel Schneiderman | Chief Officer | Profile | |
| Graeme Currie | Chief Officer | Profile |
About Pasithea Therapeutics Management Performance
The success or failure of an entity such as Pasithea Therapeutics often depends on how effective the management is. Pasithea Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Pasithea management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Pasithea management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.94) | (0.90) | |
| Return On Capital Employed | (0.68) | (0.71) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | (0.68) | (0.65) |
Please note, the imprecision that can be found in Pasithea Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Pasithea Therapeutics Corp. Check Pasithea Therapeutics' Beneish M Score to see the likelihood of Pasithea Therapeutics' management manipulating its earnings.
Pasithea Therapeutics Workforce Analysis
Traditionally, organizations such as Pasithea Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Pasithea Therapeutics within its industry.Pasithea Therapeutics Manpower Efficiency
Return on Pasithea Therapeutics Manpower
| Revenue Per Employee | 60.8K | |
| Revenue Per Executive | 60.8K | |
| Net Loss Per Employee | 1.9M | |
| Net Loss Per Executive | 1.9M | |
| Working Capital Per Employee | 1.8M | |
| Working Capital Per Executive | 1.8M |
Additional Tools for Pasithea Stock Analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.